BACKGROUND: There are recognized needs to identify determinants of influenza vaccine effectiveness (VE), including the effect of repeated annual vaccination. METHODS: We recruited 321 households with 1426 members, including 833 children, and followed them during the 2012-2013 influenza season; specimens were collected from subjects with reported acute respiratory illnesses. We estimated the effectiveness of documented influenza vaccination in preventing laboratory-confirmed influenza, using adjusted Cox proportional hazards models. Antibody titers in a subset of subjects were determined by a hemagglutination inhibition assay to determine the subjects' preseason susceptibility to influenza. RESULTS: Influenza was identified in 76 (24%) households and 111 (8%) individuals. VE point estimates indicated significant protection in adults (48%; 95% confidence interval [CI], 1%-72%), similar protection in children aged 9-17 years (49%; 95% CI, -16% to 78%), but no evidence of effectiveness in children aged <9 years (-4%; 95% CI, -110% to 49%). Lower VE was observed in those vaccinated in both the current and prior seasons, compared with those vaccinated in the current season only; susceptibility titers against type A but not type B were consistent with this observation. Residual protection from vaccination in the prior season was indicated by both VE and serologic results. CONCLUSIONS: Prior vaccination appears to modify VE by both residual protection and reduced vaccine response.
BACKGROUND: There are recognized needs to identify determinants of influenza vaccine effectiveness (VE), including the effect of repeated annual vaccination. METHODS: We recruited 321 households with 1426 members, including 833 children, and followed them during the 2012-2013 influenza season; specimens were collected from subjects with reported acute respiratory illnesses. We estimated the effectiveness of documented influenza vaccination in preventing laboratory-confirmed influenza, using adjusted Cox proportional hazards models. Antibody titers in a subset of subjects were determined by a hemagglutination inhibition assay to determine the subjects' preseason susceptibility to influenza. RESULTS: Influenza was identified in 76 (24%) households and 111 (8%) individuals. VE point estimates indicated significant protection in adults (48%; 95% confidence interval [CI], 1%-72%), similar protection in children aged 9-17 years (49%; 95% CI, -16% to 78%), but no evidence of effectiveness in children aged <9 years (-4%; 95% CI, -110% to 49%). Lower VE was observed in those vaccinated in both the current and prior seasons, compared with those vaccinated in the current season only; susceptibility titers against type A but not type B were consistent with this observation. Residual protection from vaccination in the prior season was indicated by both VE and serologic results. CONCLUSIONS: Prior vaccination appears to modify VE by both residual protection and reduced vaccine response.
Authors: Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Anne-Luise Winter; James A Dickinson; Jennifer L Gardy; Jonathan Gubbay; Kevin Fonseca; Hugues Charest; Natasha S Crowcroft; Monique Douville Fradet; Nathalie Bastien; Yan Li; Mel Krajden; Suzana Sabaiduc; Martin Petric Journal: Clin Infect Dis Date: 2012-04-26 Impact factor: 9.079
Authors: E Kissling; M Valenciano; A Larrauri; B Oroszi; J M Cohen; B Nunes; D Pitigoi; C Rizzo; J Rebolledo; I Paradowska-Stankiewicz; S Jiménez-Jorge; J K Horváth; I Daviaud; R Guiomar; G Necula; A Bella; J O'Donnell; M Głuchowska; B C Ciancio; A Nicoll; A Moren Journal: Euro Surveill Date: 2013-01-31
Authors: Timo Vesikari; Markus Knuf; Peter Wutzler; Aino Karvonen; Dorothee Kieninger-Baum; Heinz-Josef Schmitt; Frank Baehner; Astrid Borkowski; Theodore F Tsai; Ralf Clemens Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: John J Treanor; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Mark G Thompson; Po-Yung Cheng; Joshua G Petrie; Geraldine Lofthus; Jennifer K Meece; John V Williams; Lashondra Berman; Caroline Breese Hall; Arnold S Monto; Marie R Griffin; Edward Belongia; David K Shay Journal: Clin Infect Dis Date: 2012-07-25 Impact factor: 9.079
Authors: Marie R Griffin; Arnold S Monto; Edward A Belongia; John J Treanor; Qingxia Chen; Jufu Chen; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Gerry Lofthus; Joshua G Petrie; Jennifer K Meece; Caroline Breese Hall; John V Williams; Paul Gargiullo; LaShondra Berman; David K Shay Journal: PLoS One Date: 2011-08-12 Impact factor: 3.240
Authors: Kate Russell; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Brendan Flannery Journal: Vaccine Date: 2018-02-28 Impact factor: 3.641
Authors: Joshua G Petrie; Marisa C Eisenberg; Sophia Ng; Ryan E Malosh; Kyu Han Lee; Suzanne E Ohmit; Arnold S Monto Journal: Am J Epidemiol Date: 2017-12-15 Impact factor: 4.897
Authors: Danuta M Skowronski; Catharine Chambers; Gaston De Serres; Suzana Sabaiduc; Anne-Luise Winter; James A Dickinson; Jonathan B Gubbay; Kevin Fonseca; Steven J Drews; Hugues Charest; Christine Martineau; Mel Krajden; Martin Petric; Nathalie Bastien; Yan Li; Derek J Smith Journal: J Infect Dis Date: 2017-04-01 Impact factor: 5.226
Authors: Marieke L A de Hoog; Roderick P Venekamp; Roger A M J Damoiseaux; Anne G M Schilder; Elisabeth A M Sanders; Henriette A Smit; Patricia C J L Bruijning-Verhagen Journal: Ann Fam Med Date: 2019-01 Impact factor: 5.166
Authors: Joshua G Petrie; Emily T Martin; Rachel Truscon; Emileigh Johnson; Caroline K Cheng; E J McSpadden; Ryan E Malosh; Adam S Lauring; Lois E Lamerato; Maryna C Eichelberger; Jill M Ferdinands; Arnold S Monto Journal: Vaccine Date: 2019-02-07 Impact factor: 3.641
Authors: Mark G Thompson; Jessie Clippard; Joshua G Petrie; Michael L Jackson; Huong Q McLean; Manjusha Gaglani; Evelyn C Reis; Brendan Flannery; Arnold S Monto; Lisa Jackson; Edward A Belongia; Kempapura Murthy; Richard K Zimmerman; Swathi Thaker; Alicia M Fry Journal: Pediatr Infect Dis J Date: 2016-03 Impact factor: 2.129